Langbahn Team – Weltmeisterschaft

Canbisol

Canbisol
Clinical data
Drug classCannabinoid
ATC code
  • none
Identifiers
  • (6aR,9R,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,8,9,10,10a-hexahydrobenzo[c]chromene-1,9-diol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H38O3
Molar mass374.565 g·mol−1
3D model (JSmol)
  • Oc1cc(C(C)(C)CCCCCC)cc(c1C2C3)OC(C)(C)C2CCC3O
  • InChI=1S/C24H38O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,17-19,25-26H,6-12,15H2,1-5H3/t17?,18-,19-/m0/s1 ☒N
  • Key:UEKGZFCGRQYMRM-MNNMKWMVSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Canbisol (Nabidrox), is a synthetic cannabinoid derivative that is the dimethylheptyl homologue of 9-nor-9β-hydroxyhexahydrocannabinol (HHC). It is a potent agonist at both the CB1 and CB2 receptors, with a binding affinity of 0.1 nM at CB1 and 0.2 nM at CB2.[1] It is mainly used in scientific research, in receptor binding studies to determine the structure and function of the cannabinoid receptors,[2][3][4] but has been made illegal in some countries due to its possible abuse potential as a cannabinomimetic drug.[5]

See also

References

  1. ^ Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L, et al. (September 1997). "Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase". Journal of Medicinal Chemistry. 40 (20): 3228–33. doi:10.1021/jm970126f. PMID 9379442.
  2. ^ Rhee MH, Nevo I, Bayewitch ML, Zagoory O, Vogel Z (December 2000). "Functional role of tryptophan residues in the fourth transmembrane domain of the CB(2) cannabinoid receptor". Journal of Neurochemistry. 75 (6): 2485–91. doi:10.1046/j.1471-4159.2000.0752485.x. PMID 11080201. S2CID 18339666.
  3. ^ Rhee MH (September 2002). "Functional role of serine residues of transmembrane dopamin VII in signal transduction of CB2 cannabinoid receptor". Journal of Veterinary Science. 3 (3): 185–91. doi:10.4142/jvs.2002.3.3.185. PMID 12514330.
  4. ^ Zhang R, Hurst DP, Barnett-Norris J, Reggio PH, Song ZH (July 2005). "Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template". Molecular Pharmacology. 68 (1): 69–83. doi:10.1124/mol.104.007823. PMID 15840841. S2CID 6488891.
  5. ^ The Misuse of Drugs Act 1971 (Amendment) Order 2009